EGFR and neoplasm: Notably, quite a part of uncommon EGFR mutations are “untested” with the polymerase chain reaction (PCR)-based assay commonly used in clinical practice, together with the adequacy, quality, and heterogeneity of tumor samples in detection techniques, which results in the inaccuracy and bias in the reported incidence of less common EGFR mutations (27).